ArticleTranslational cancer research2019
STX4 expression is associated with classification, clinical stage and lymphatic metastasis in ovarian cancer.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Silencing of STX4 inhibits the proliferation, migration and invasion of ovarian cancer cells via EMT/MMP2/ CCND1 signaling pathway.Journal of ovarian research · 2025Article
- Clinicopathologic significance of FUT8, STX4, and calpain2 expression in ovarian cancer.American journal of translational research · 2025Article
- Article
- Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer (OC) is one of the most common malignant tumors in female reproductive system and 55-75% of the patients relapsed after surgery and standard postoperative chemotherapy and radiotherapy. The SNARE proteins, syntaxin4 (STX4) is localized in the plasma membrane to drive vesicle fusion which of integrin-containing vesicles with the plasma membrane is the final step of integrins delivery and play a role in the occurrence, development, invasion and metastasis of cancer cells.
methodsImmunohistochemistry analysis was used to investigate the correlation between STX4 expression and clinicopathological features of epithelial OC patients.
resultsOur study demonstrated that STX4 was positively expressed in OC tissues and the expression of STX4 was positively correlated with the clinical stage of human OC classification and node metastasis, suggesting that STX4 was involved in the occurrence and development of OC.
conclusionsOur findings suggested that STX4-targeted treatment could be used as a potential therapeutic strategy for OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.